Navigate Fool.com
Will IMGN beat
the market?



Community Rating: 4 Stars: Favorite

12.80 0.02 (0.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.88
Previous Close $12.78
Daily Range $11.78 - $13.24
52-Week Range $11.78 - $20.25
Market Cap $1.1B
P/E Ratio -34.86
Dividend (Yield) $0.00 (0.0%)
Volume 1,531,738
Average Daily Volume 836,930
Current FY EPS -$0.72

How do you think IMGN
will perform against the market?

Top IMGN Bull/Bear Pitches


TMFBreakerThiel (< 20)
Submitted September 28, 2010

Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has … More

0 Replies Reply Report this Post

NetscribeHealthC (< 20)
Submitted February 14, 2007

ImmunoGen develops therapeutics for the treatment of cancer. The company‚Äôs tumor-activated prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to treat cancer cel … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Milestone Payments Push ImmunoGen to a Q2 Profit

A number of amortized milestone and licensing payments help push ImmunoGen to a surprise quarterly profit.

Enanta Pharmaceuticals, Inc., ImmunoGen, Inc. and Prana Biotechnology Ltd Could Be Big Movers in Hea

Morning movers in healthcare

Sector Update: Healthcare Shares Flat Pre-Market; ImmunoGen up 4% on Q4 Results

Sector Update: Healthcare

GlaxoSmithKline and Personalized Medicine Take Another Leap Forward

GlaxoSmithKline recently won an accelerated approval for the first combination melanoma therapy. This relatively easy label expansion holds important lessons for pharmaceutical companies, and investors.

Earnings Reaction History: ImmunoGen, Inc., 42.9% Follow-Through Indicator, 5.8% Sensitive

JPMorgan Healthcare Conference Highlights: ImmunoGen

ImmunoGen kicks off the JPMorgan Healthcare Conference by focusing on its wholly-owned compounds and emphasizing its new linking technology.

AbbVie Inc. Invests in Precision-Bombing Cancer Therapies

With annual sales likely to reach $10 billion, Humira is rocking. The party can't last forever, though. AbbVie could be filling that gap it leaves behind with an exciting new way to fight cancer.

"Star Trek" Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods

The next-generation of cancer-fighting agents could be right around the corner.

Will Seattle Genetics Have a Happy New Year?

This biopharma could be a big winner in the New Year.

See More IMGN News...





ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website: http://www.immunogen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks